Abstract
Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.
| Original language | English |
|---|---|
| Pages (from-to) | 2174-2178 |
| Number of pages | 5 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 72 |
| Issue number | 12 |
| Publication status | Published - Dec 1 2014 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
[Current status and prospects of immunotherapy for castration-resistant prostate cancer]. / Yatsuda, Junji; Eto, Masatoshi.
In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 72, No. 12, 01.12.2014, p. 2174-2178.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - [Current status and prospects of immunotherapy for castration-resistant prostate cancer]
AU - Yatsuda, Junji
AU - Eto, Masatoshi
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.
AB - Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.
UR - http://www.scopus.com/inward/record.url?scp=84922219742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922219742&partnerID=8YFLogxK
M3 - Article
C2 - 25518354
AN - SCOPUS:84922219742
VL - 72
SP - 2174
EP - 2178
JO - Astrophysical Journal
JF - Astrophysical Journal
SN - 0004-637X
IS - 12
ER -